LOS ANGELES, Nov. 10, 2005 (PRIMEZONE) -- BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, today announced the availability of a new audio interview with Arc Rajtar, Chief Technology Officer of MIV Therapeutics (OTCBB:MIVT); (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems.
In the interview, Mr. Rajtar discussed recently announced interim findings of an independent, long-term animal study of MIVT's novel technology to create new, highly biocompatible and bio-friendly coatings for vascular stents, including drug-eluting stents and other medical devices. Stents are widely used medical devices designed to prop open clogged blood vessels to maintain healthy blood flow to the heart and throughout the body, but current products are associated with a number of undesirable effects that result from insufficient biocompatibility.
"Our objective was to develop a coating which will be as biocompatible as possible and biologically safe," said Mr. Rajtar. "The results from 1-month and 3-month long arms of this study confirmed our earlier expectations of superb biocompatibility and total safety of our Hydroxyapatite coatings."
The final results of the 6 Month long study are expected next week.
MIVT has developed both ultra-thin as well as thicker, drug-eluting stent coatings based on a highly biocompatible material called Hydroxyapatite (HAp). The coatings are being conducted at the Center for Research in Cardiovascular Interventions of The Methodist Hospital Research Institute in Houston, TX. The findings were reported to the scientific community recently at the Transcatheter Cardiovascular Therapeutics 2005 conference, the field's most important annual conference.
"In its thicker, submicron version which is also highly porous, we see our HAp coatings as exceptional vehicle for short-term and long-term drug delivery purposes," Mr. Rajtar said. "This is exceptional because at the present time there is no other coating which can match the biocompatibility of Hydroxyapatite and provide drug eluting capability at the same time."
Mr. Rajtar explained that during animal trials, MIVT's stent coatings did not cause any adverse reactions, including excessive stenosis (re-clogging of arteries through unwanted tissue growth), and no thrombus (blood clot), both of which are growing concerns in connection with the drug-eluting systems now available for use in the health care marketplace.
The entire streaming audio interview with Mr. Rajtar can be accessed free of charge by visiting http://www.BiomedDiscoveries.com.
About MIV Therapeutics, Inc.
MIV Therapeutics Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's drug eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com.